Your cart is empty
Start Shopping$40.00
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
CAS Number | 218949-48-5 |
Molar Mass | 5135.86 g/mol |
Amino Acid Sequence | Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) |
PubChem CID | 146681838 |
Primary Research Area |
Reduce Visceral Adipose Tissue (VAT) in HIV-infected patients with lipodystrophy Insulin Resistance Obesity Nonalcoholic Fatty Liver Disease (NAFLD) GHRH Receptor Agonist Stimulate GH/IGF-1 Improve Metabolic Profile Improve Fat Quality |
Purity | >99% |
Research Summary | Description |
---|---|
Tesamorelin improves fat quality independent of changes in fat quantity |
Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH). Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213. |
The growth hormone releasing hormone analogue, Tesamorelin, decreases muscle fat and increases muscle area in adults with HIV |
Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue). Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173. |
Effects of Tesamorelin on nonalcoholic fatty liver disease in HIV: A randomized, double-blind, multicenter trial |
Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups. Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5. |
Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH).
Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213.
Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue).
Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173.
Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups.
Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5.
Your cart is empty
Start Shopping